The burgeoning popularity of retatrutide, initially for diabetes , is creating significant attention within the United Kingdom , prompting a notable shift in hormone trends. Availability these medications remains a complex landscape, with NHS coverage currently limited and independent providers offering treatment at a higher cost . Concerns are bei